Drug Trial Radar · NCT06703658
A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Nov 2, 2024
Primary completion
Mar 13, 2025
Study completion Mar 13, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase I study will gather important information on the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5004 in both healthy Japanese participants and Japanese participants with T2DM.
Conditions
- Healthy Participants
- Type 2 Diabetes
Interventions
AZD5004(Part A)Drug
Single dose of AZD5004 oral on Day1
Placebo(Part A)Drug
Single dose of placebo oral on Day1
AZD5004(Part B)Drug
AZD5004 will be administered as an oral tablet once daily.
Placebo(Part B)Drug
Placebo will be administered as an oral tablet once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PartA: Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: From screening (Day -28) to last follow up visit (Day 8)
- PartB: Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: From screening (Day -28) to last follow up visit (Day 119 )
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Osaka, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.